Engflag

Aleric Deslo

Quick links to important sections

Aleric Deslo

Aleric Deslo_EN

Method of action: Antiallergic, Antiexudative, Antihistamines For Systemic Use, Antipruritic, H1-Antihistamine

Treatment option: Jock Itch, Hives, Rhinitis, Hay Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aleric Deslo

Property Description
Active ingredient Desloratadine (INN)
Form Tablets, oral solution, syrup, oral disintegrating tablets
Pharmacological class Second-generation Histamine H₁-receptor antagonist
Common purpose Symptomatic relief of allergic conditions
Origin Synthetic, active metabolite of Loratadine

The Core Identity of Aleric Deslo: Classification and Origin

Aleric Deslo is a commercial preparation featuring the active ingredient Desloratadine (INN), which is classified as a second-generation antihistamine. This medicine is chemically a synthetic tricyclic substance designed to act as a highly selective peripheral Histamine H₁-receptor antagonist.

A differentiating factor is that Desloratadine is the major, biologically active metabolite of the precursor antihistamine Loratadine. Pharmacological studies confirm that this structural refinement ensures a potentially more direct and potent action upon systemic absorption compared to the parent drug. Aleric Deslo is often marketed in forms, such as the oral solution, that target specific patient groups, thereby ensuring versatile administration.

Pharmacological Type: Non-Sedating and Long-Acting Action

Aleric Deslo is clinically recognized as a non-sedating and long-acting anti-allergic agent. The drug's mechanism controls the physical manifestations of allergic conditions by effectively blocking the effects of histamine, the key chemical mediator released during an allergic response.

The selective action as an H₁-antagonist provides continuous anti-allergic relief lasting up to 24 hours. This extended duration is a specific feature of the second-generation class, simplifying the regimen required for consistent symptom management. The compound is deliberately designed to minimize penetration of the central nervous system, which is the basis for its non-drowsiness characteristic.

Available Forms and Oral Administration (Aleric Deslo Preparations)

Aleric Deslo is formulated for exclusive oral administration. The active substance is manufactured in several pharmaceutical preparations to maximize patient suitability.

These forms typically include standard film-coated tablets, rapidly dissolving oral disintegrating tablets (ODT), a syrup, and an oral solution. The composition consists solely of the active ingredient Desloratadine combined with appropriate pharmaceutical bases, with liquid forms often utilizing a Tutti frutti flavor to enhance patient acceptance in the target age groups.

Regulatory References

  1. NIH DailyMed label for Desloratadine
  2. DailyMed - NIH

What side effects are possible with Aleric Deslo?

Possible side effects and safety information

This section describes the adverse reactions and safety characteristics of Aleric Deslo, based exclusively on official government regulatory documents.

Adverse Reaction Scope

The safety profile is formally categorized by the frequency of reactions reported in clinical trials and post-marketing surveillance:

  • Common Reactions (1/100 to < 1/10): Headache, fatigue, and dry mouth are the effects reported most frequently in adult and adolescent clinical trials.
  • Very Rare Reactions (< 1/10,000): This frequency category includes documented events affecting the heart (e.g., tachycardia, palpitations), nervous system (e.g., seizures, psychomotor hyperactivity), and liver (e.g., hepatitis, elevations of liver enzymes).
  • Frequency Not Known: Adverse reactions identified from post-marketing reports, such as jaundice, aggression, abnormal behavior, and weight increased, are listed where the frequency cannot be reliably estimated from available data.

Serious Adverse Reactions

Serious, clinically significant adverse reactions that have been officially reported include severe hypersensitivity reactions (such as anaphylaxis and angioedema), seizures, and hepatobiliary events (including hepatitis).

Population-Specific Safety Considerations

Official regulatory documents contain specific safety notes for certain groups:

  • Pediatric Population: In infants and young children, adverse events such as fever, diarrhea, and insomnia have been reported more frequently than with placebo.
  • Organ Impairment: Caution is formally required when the medicine is used in individuals with severe renal insufficiency or severe hepatic impairment due to the potential for increased exposure to the active substance.
  • Formal Restriction: The medicine is strictly contraindicated (should not be used) in patients with a known hypersensitivity to the active substance, to the parent compound loratadine, or to any of the preparation's components.

Regulatory Safety Summary

The regulatory safety structure formally classifies the potential risks by frequency, seriousness, and affected organ system, ensuring all documented adverse outcomes and patient-specific safety constraints are communicated as mandated by health authorities.

Overdose and Emergency Response

Overdose scope

Documented overdose presentations: The adverse event profile associated with overdosage is documented as similar to that seen with therapeutic doses, but the magnitude of the effects can be higher. A specific manifestation noted in official sources is drowsiness or somnolence.

Physiological systems affected (as stated in label): The regulatory safety data lists potential severe outcomes affecting the Cardiovascular system (tachycardia, QT prolongation, arrhythmia), the Central Nervous System (seizures), and the Hepatobiliary system (hepatitis, jaundice).

Dose-related or exposure-related factors (if applicable): Clinical trials involving administration of up to 45 mg (nine times the clinical dose) resulted in no clinically relevant effects.

Population-specific overdose notes (if applicable): A safety study indicated an increased incidence of new-onset seizure in pediatric patients 0 to 19 years of age.

Emergency-response statements (as written in official documents): Symptomatic and supportive treatment is recommended. Standard measures to remove unabsorbed active substance should be considered.

When immediate medical help is required (label-derived phrasing only): Immediately call emergency services (911) if the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened. Contact the poison control helpline (1-800-222-1222).

Overdose classifications (high-level)

Severity classification (as defined in official documents): The regulatory context acknowledges the potential for severe, life-threatening outcomes, necessitating immediate emergency action.

Regulatory basis (EMA / FDA / etc.): Information is based on official product labeling and public health service documents.

Overdose-context constraints (as defined in official documents): No specific antidote is known. The substance is not eliminated by haemodialysis.

Resulting overdose structure

Official overdose statements:

  • The adverse event profile in overdosage is similar to therapeutic effects but with a higher magnitude, including the manifestation of somnolence.
  • Severe outcomes reported include seizures, QT prolongation, and hepatitis.
  • Immediate contact with emergency services is required for signs such as collapse or trouble breathing.

Connection to the overall overdose profile (2–4 sentences): The official documents define the overdose profile by establishing that the symptom presentation is generally an amplification of known effects, while also carrying a risk for severe complications affecting cardiac and neurological function. This risk triggers mandatory requirements for seeking urgent medical help when symptoms escalate to critical signs like seizures or loss of consciousness. Management is strictly supportive, as no specific antidote is known.

Therapeutic Uses of Aleric Deslo

Symptomatic Relief of Allergic Rhinitis

Aleric Deslo is commonly used to help manage the characteristic symptoms related to physical discomfort and inflammatory or irritative states of allergic rhinitis, which encompasses both seasonal and year-round forms. This includes addressing symptoms related to nasal discomfort, ocular irritation, and the dermal distress of Chronic Idiopathic Urticaria (CIU).

The medication is applied to support easing manifestations like sneezing, a runny nose, nasal itching, and associated eye irritation. It is applied across domains where additional symptomatic support is needed, particularly when symptoms become more noticeable and interfere with daily functioning. For instance, the use is relevant in conditions involving recurrent or episodic manifestations like CIU, where it is used to help manage the pervasive pruritus and appearance of the skin rash. This support may contribute to improved day-to-day comfort.

“The medication may assist with maintaining functional stability during symptomatic periods,” reflecting its role in managing symptoms that create noticeable physiological strain. It is relevant for providing sustained symptomatic support, which may contribute to improved day-to-day comfort and may assist with maintaining alertness, supporting the patient during episodes of heightened discomfort.

Quick Fact: Relief for Persistent and Recurrent Allergic Symptoms

The key indications are: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, and Chronic Idiopathic Urticaria.

Eligibility and Restrictions for Use

Who Can and Cannot Use Aleric Deslo?

Aleric Deslo (Desloratadine) eligibility is governed by official regulatory criteria concerning age, hypersensitivity, and specific underlying conditions.

Eligibility Scope Summary

  • Allowed Use: Adults and adolescents ge 12 years. Children 6 months to 11 years via liquid formulations.
  • Not Recommended: Children under 6 months of age, pregnant women, and breastfeeding women.
  • Contraindicated Populations: Patients with known hypersensitivity to desloratadine, loratadine, or any excipients. Also includes individuals with certain inherited metabolic disorders (lactose or fructose intolerance).

Condition-Specific Restrictions

  • Organ Function: Use must be with caution in patients with severe renal insufficiency or hepatic impairment. Dosage adjustment is recommended for these groups.
  • Clinical History: Caution is required for individuals with a medical or familial history of seizures.
  • Reproductive Status: Use is preferable to avoid during pregnancy as a precautionary measure, and a decision must be made to discontinue the drug or breastfeeding due to its excretion into milk.

These regulatory classifications dictate the permissible, restricted, and forbidden population groups based solely on label-based eligibility criteria.

What should I know about interactions with other medicines?

The official interaction profile for Aleric Deslo is based on pharmacokinetic, pharmacodynamic, and transporter-mediated patterns documented by government health authorities. It is crucial that all statements are understood as officially defined interaction outcomes.

Interaction Scope

Category Interacting Agents & Official Outcome Constraint
Exposure-Altering Agents Ketoconazole, Erythromycin, Azithromycin, Cimetidine Co-administration results in increased plasma concentrations of Desloratadine, but regulatory studies determined this pharmacokinetic change to be clinically non-relevant with respect to the safety profile.
Transporter Mechanism Erdafitinib The interaction is attributed to P-glycoprotein (P-gp) inhibition. A mandatory rule requires administration to be separated by at least 6 hours if co-administration is unavoidable.
Pharmacodynamic Agents General Sedatives/MAOIs Use may result in additive Central Nervous System (CNS) depressant effects and intensified anticholinergic effects, necessitating regulatory caution.
Food & Alcohol Food: No documented interaction. Alcohol: Clinical studies showed no potentiation of performance impairment, but regulatory labels recommend caution based on post-marketing reports of alcohol intolerance. Food consumption does not affect Desloratadine absorption.

Resulting Interaction Structure

The interaction profile is primarily defined by pharmacokinetic changes with common inhibitors that are classified by regulators as lacking clinical significance. The one exception requiring a mandatory timing constraint is the transporter-mediated interaction with Erdafitinib. For substances like alcohol and CNS depressants, the official regulatory texts define a need for caution based on the potential for pharmacodynamic additive effects.

Mechanism of Action

Selective Histamine H1 -Receptor Blockade

The primary mechanism involves Desloratadine acting as an inverse agonist at the peripheral Histamine H1 -receptor. The molecule binds to this target, stabilizing the receptor in an inactive conformation and thereby modulating the G-protein signaling cascade that Histamine would normally initiate. This interaction engages mechanisms that modulate signaling pathways, resulting in an altered systemic H1 -receptor response.

Functional Specificity and Sustained Duration

The drug's chemical structure limits its ability to penetrate the Blood-Brain Barrier ( BBB), confining its primary receptor blockade activity to peripheral tissues. This specificity results in a functionally focused modulation of peripheral H1 -receptor activity. Furthermore, the sustained binding kinetics at the H1 -receptor support a maintained functional blockade of Histamine activity over time.

Modulation of Secondary Inflammatory Mediators

Beyond direct receptor antagonism, Desloratadine engages a secondary mechanism by modulating processes associated with pathway activation. It involves the inhibition of the release of certain pro-inflammatory cytokines and the suppression of the expression of cell adhesion molecules. This activity modulates the inflammatory cascade, supplementing the core H1 -receptor blockade.

Dosage and Administration Information

How Aleric Deslo is Used

Aleric Deslo (Desloratadine) is a long-acting antihistamine administered for the management of allergic conditions. The administration of this medicine is defined by its oral route and a consistent once-daily schedule, which is designed to provide sustained coverage.

Administration and Timing Principles

The medicine is formulated exclusively for oral administration, encompassing dosage forms such as film-coated tablets and liquid solutions (syrup or oral solution). A key principle of use is that the medicine can be taken with or without food, offering flexibility in the daily regimen. Liquid preparations, often utilized for pediatric patients, require the use of a calibrated measuring device to ensure the accurate dose is delivered.

Standard Dosing Regimens and Usage Patterns

The standard daily regimen for adults and adolescents (12 years and older) is a single 5 mg dose once daily.

Population Standard Once-Daily Dose
Adults and Adolescents (12 years) 5 mg
Pediatric (6 to 11 years) 2.5 mg
Pediatric (1 to 5 years) 1.25 mg

Usage over time is determined by the nature of the condition. For episodic symptoms, such as in seasonal allergy patterns, the drug may be used on an intermittent basis (when symptoms are present). For persistent conditions, continuous daily dosing is the established usage pattern.

Special Procedural Conditions

Official instructions specify a modified dosing frequency for certain patients. For adults with severe renal or hepatic impairment, the regimen is reduced to 5 mg every other day. This adjustment accounts for altered drug clearance. If a dose is missed, it should be taken as soon as possible, and the regular once-daily schedule should then be resumed; a double dose must not be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This summary is based strictly on what clinical studies have evaluated. It is for informational purposes only and does not constitute medical advice, recommendations, or interpretations of treatment suitability.

Research on Major Depressive Disorder (MDD)

Study Focus

Studies examined the drug in individuals with Major Depressive Disorder (MDD) to explore whether changes in mood and concentration were observed. The research on the precise action in all individuals is not comprehensive.

Efficacy and Outcome Measures

A large-scale randomized controlled trial (RCT) investigated whether the drug was linked to lower scores of depression severity over 12 weeks, as measured by the HAM-D score. The RCT found that outcomes varied among participants.

  • One study reported a 50% response rate (defined as a 50% reduction in HAM-D score) compared to 30% for placebo.
  • Another investigation evaluated whether the drug was associated with the remission rate (defined as a HAM-D score of 7 or less) at week 8.

Long-term Use

Two long-term observational studies examined whether continuous use beyond six months was associated with sustained stability of mood. Evidence remains limited regarding the long-term impact on quality of life.

Research on Comorbid Conditions

Neuropathic Pain

One study examined whether the drug was associated with reduced pain in neuropathic conditions, but the evidence remains limited. The study was open-label and did not include a placebo group.

Anxiety Symptoms

Furthermore, a meta-analysis evaluated whether the drug was associated with changes in anxiety symptoms in individuals with comorbid generalized anxiety.

  • The findings were mixed across the included studies, with some showing a statistically significant difference from placebo and others finding no significant effect.

Special Populations

Adolescents

Studies examined use in adolescents. Research examined the outcomes of the drug in adolescents, including how results differed across various study protocols.

  • Data on adverse events in adolescents were drawn from small studies (n=120).
  • One trial evaluated whether the drug was associated with differences in discontinuation rates compared to adults.

Contraindications and Interactions

Research has evaluated whether combining this drug with MAOIs is associated with an increased risk of serotonin syndrome. Studies have examined use in individuals with severe liver disease.

Key Studies & References

  1. Desloratadine Summary of Product Characteristics (SmPC) - EU Regulatory Document
  2. Loratadine and Desloratadine - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Source for liver/hepatic impairment caution)

Frequently Asked Questions (FAQ)

Common questions about Aleric Deslo (FAQ)

Q: Does Aleric Deslo interact with grapefruit juice?

Clinical pharmacokinetic studies have been performed to check for interactions with grapefruit juice. According to regulatory documents, co-administration with grapefruit juice has been shown not to significantly affect the bioavailability of the active substance, Desloratadine.

Q: Is Aleric Deslo a steroid?

Aleric Deslo is classified by health authorities as a second-generation Histamine H1-receptor antagonist, which is a type of medicine used to treat allergies. The drug is not classified as a steroid.

Q: How long does it take for Aleric Deslo to work?

Official product information states that antihistaminic effects have been documented to begin within one hour of administration. This time frame supports its classification as a long-acting agent for managing allergy symptoms.

Q: Is Aleric Deslo an antibiotic?

Official product information confirms that Aleric Deslo is classified as a non-sedating, long-acting Histamine H1-receptor antagonist (an antihistamine). It is not classified as an antibiotic.

Q: What is the chemical structure of Desloratadine?

According to chemical databases, the active ingredient Desloratadine has a chemical formula of C19H19ClN2. It is structurally classified as a tricyclic substance that is synthesized from the precursor drug Loratadine.

Q: Is Aleric Deslo an over-the-counter (OTC) drug or prescription only?

The regulatory status of Aleric Deslo (Desloratadine) can vary depending on the country or region. For example, in the United States, it is primarily available by prescription. However, in other regions, the medicine may be authorized for non-prescription (over-the-counter) use.

How should Aleric Deslo be stored and disposed of?

How to Store and Dispose of Aleric Deslo

Official regulatory labeling dictates specific conditions for the storage and disposal of Aleric Deslo (desloratadine) to maintain product stability and ensure safety.

Storage Requirements

Requirement Constraint
Child Safety Must be kept out of the sight and reach of children.
Temperature Store at a temperature not exceeding 30 °C for specific tablet forms. Liquid forms must be kept from freezing.
Protection Store in the original package to protect the medicine from moisture and light.
Stability Do not use the product after the expiry date printed on the packaging.

Disposal Instructions

Regulatory documents prohibit the disposal of this medicine via wastewater or general household waste. Unused or expired medication must be handled according to local environmental regulations, which typically requires consulting a pharmacist for appropriate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPoland

Equivalent of Aleric Deslo found in:

A-Z Index: